Horse antibody cocktail aims to revive blood cell production
NCT ID NCT01624805
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 37 times
Summary
This phase 2 trial tests a combination of horse anti-thymocyte globulin, cyclosporine, steroids, and a growth factor in 140 adults with aplastic anemia or low-risk myelodysplastic syndrome. The goal is to see if this immune-suppressing and blood-cell-boosting approach can improve blood counts. Participants must be 18 or older and not eligible for a stem cell transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
horse anti-thymocyte globulin (hATG), cyclosporine, methylprednisolone, and filgrastim or pegfilgrastim
What this could lead to
If successful, this combination could improve blood cell counts and reduce transfusion needs for people with aplastic anemia or low-risk myelodysplastic syndrome.
What could go wrong
This is a mid-stage trial with only 140 participants, so results may not apply to everyone. The treatment suppresses the immune system, which can increase infection risk and other side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.